Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



Long term beta adrenergic receptor blockade following myocardial infarction promotes myocardial angiogenesis

16 Mar 05

Beta blockers reduce heart rate and myocardial contractility thereby reducing myocardial work load. Diastolic perfusion time is also lengthened by beta blockers supporting the use of this drug class as acute and chronic treatment following myocardial infarction. Studies have demonstrated that beta blockers can reduce total mortality, nonfatal myocardial infarction and sudden death in patients who have already suffered a myocardial infarction by 20-30%. Despite the potential benefit of beta block

Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

16 Mar 05

Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus

Testing times for Tysabri

11 Mar 05

Biogen Idec and Elan have announced the voluntary suspension from sale and withdrawal from clinical trials of Tysabri, the companies' novel therapy for the treatment of relapse remitting multiple sclerosis (RRMS). This move has already slashed share prices of both companies. Even if Tysabri is relaunched with some form of black-box warning, doubts will surely linger over its long-term safety.

The Best of Both Worlds

08 Mar 05

Imagine the benefits of working for a global organisation which turns over over £4 billion per year worldwide but is primarily family owned and complete with family values? This is exactly what Merck offers.
Pharmaceutical Field

Sankyo and Daiichi plans show Japanese consolidation goes on

04 Mar 05

Sankyo and Daiichi Pharmaceutical are considering merging in October 2005 to become Japan's number two drugmaker, as competition in the market continues to intensify. Following the announcement of mergers between Yamanouchi and Fujisawa, and Dainippon and Sumitomo, will continuous domestic consolidation ensure a place for global integration in the face of western pressure?

Bipolar Disorder

03 Mar 05

Bipolar affective disorder – previously referred to as manic depression – is a psychiatric disorder affecting at least 1% of the UK population, and depending on the definition used, may affect as many as 5% of the population. A recent World Health Organization analysis of the major global causes of disability, economic and social burden, indicated that bipolar affective disorders are ranked in the top ten, and account for 2.5% of total years lost to disability across all age groups.
CSF Medical Communications

Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care

02 Mar 05

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2003, analysts predict that the sector will grow to $60 billion by 2010, yielding a compound annual growth rate of 8% over this period. Major changes are however occurring in the oncology market. Cytotoxics, a cornerstone of oncology, are reaching patent expiry and the last cytotoxic genericization is expec

Blockbuster brands generate generic goals

25 Feb 05

Despite being the current gold standard and sales heavyweight of the antipsychotic market with $4 billion in global sales, Eli Lilly's Zyprexa (olanzapine) is facing legal action in the US over alleged side effects. Along with other blockbuster drugs in the market, it may also run into intense competition from generics earlier than expected, according to new research from Datamonitor.

Emerging treatments for inflammatory bowel disease (IBD)

20 Feb 05

Ulcerative colitis and Crohn’s disease, known collectively as inflammatory bowel disease (IBD) currently affects 0.5-1% of the Western world’s population. This translates to over one million people in America (525,000 Ulcerative Colitis, 490,000 Crohn's Disease) and four million people worldwide. Sufferers experience a range of gastrointestinal symptoms, including diarrhea, rectal bleeding and abdominal pain resulting in weight loss as well as other extraintestinal manifestation such as skin and

Migraine treatment - a financial headache

18 Feb 05

More than 70 million people worldwide suffer from migraines, yet despite the dramatic effects on everyday life that migraine sufferers face, new research from Datamonitor has revealed that due to economic constraints within national healthcare systems, some patients aren't getting the best available treatment.

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.